Lineage Cell Therapeutics, Inc. LCTX

1.03 0.08 8.42% as of 25 Sep
Market cap
$239.7M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.12
P/S ratio
26.40 10.54 21.04 14.20 92.84 144.62 36.85 23.15 66.21 52.25
P/FCF ratio
0.00 0.00 0.00 323.29 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(78.78) (15.77) (31.27) (25.15) (68.62) (46.81) (23.45) (19.87) (40.34) (34.96)
P/B ratio
8.87 1.30 3.03 2.90 4.43 2.78 1.16 1.25 1.39 2.37
Price to Tangible BV
394.55 5.06 39.30 14.33 12.07 7.06 2.48 1.30 1.45 2.57
EV/Sales
22.57 5.51 17.08 10.27 79.41 121.87 28.13 17.01 55.21 48.66
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(17.37) (2.27) (5.35) 142.64 (14.63) (11.27) (3.10) (2.75) (6.26) (6.81)
EV/FCF
(16.90) (2.21) (5.23) 233.83 (14.42) (11.24) (3.06) (2.63) (6.03) (6.43)
Quick Ratio
4.99 3.47 2.02 3.06 2.32 5.35 8.42 5.06 5.99 2.70
Current Ratio
5.20 3.65 2.14 3.16 2.37 5.66 8.86 5.34 6.20 2.90
Net Debt/EBITDA
2.64 2.28 1.48 2.65 1.21 1.69 0.86 0.80 1.09 0.40
Debt/Assets
0.03% 0.06% 0.09% 0.07% 0.02% 0.02% 0.06% 0.10% 0.09% 1.03%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Asset Turnover
0.13 0.09 0.08 0.10 0.03 0.02 0.03 0.04 0.02 0.05
Operating CF/Net income
0.30 1.24 1.33 (0.04) 0.55 0.96 2.73 0.67 1.53 (1.26)
Capex/Depreciation
(0.03) (1.00) (0.86) (0.60) (0.38) (0.02) (0.11) (0.43) (0.29) (0.49)
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
(105.57%) (26.77%) (32.08%) (32.27%) (46.25%) (20.01%) (11.51%) (35.86%) (13.55%) 32.44%
ROA
(56.27%) (17.37%) (19.13%) (17.62%) (30.46%) (17.69%) (10.31%) (33.46%) (12.65%) 28.30%
ROIC
0.00% (45.86%) (58.07%) (99.51%) (94.43%) (30.84%) (30.14%) (42.40%) (19.26%) (33.73%)
Return on Tangible Assets
(126.17%) (47.39%) (94.54%) (56.27%) (62.07%) (49.33%) (19.78%) (129.99%) (48.39%) 150.36%
Average Days of Receivables
22.34 24.52 30.40 7.37 4,274.73 0.80 2,485.95 272.14 321.51 71.30
Research and Development Expense of Revenue
121.80% 131.30% 175.57% 95.13% 781.25% 674.53% 510.61% 420.11% 694.74% 609.59%
Selling, General and Administrative Expense of Revenue
126.82% 191.29% 193.43% 153.08% 419.53% 852.74% 683.67% 495.71% 576.11% 479.93%
Intangible Assets out of Total Assets
0.38 0.51 0.57 0.46 0.33 0.53 0.47 0.03 0.04 0.07
Share Based Compensation of Revenue
32.65% 53.45% 51.87% 29.16% 85.72% 128.48% 101.85% 108.30% 113.71% 134.24%
Graham Net Nets
(0.03) 0.15 0.00 0.04 0.07 0.12 0.33 0.23 0.15 0.04
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.08
Earnings Yield
(16.77%) (20.00%) (11.93%) (12.20%) (10.61%) (7.74%) (4.49%) (38.46%) (5.50%) 9.88%
Free Cash Flow Yield
(5.06%) (23.63%) (15.54%) 0.31% (5.93%) (7.50%) (24.94%) (27.97%) (13.82%) (14.49%)
Revenue per Share
0.06 0.05 0.05 0.09 0.03 0.01 0.02 0.04 0.03 0.06
Operating CF per Share
(0.08) (0.12) (0.17) 0.01 (0.14) (0.13) (0.22) (0.24) (0.27) (0.43)
Capex per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 (0.01) (0.01) (0.03)
Free Cash Flow per Share
(0.08) (0.12) (0.17) 0.00 (0.15) (0.13) (0.22) (0.25) (0.28) (0.46)
Cash per Share
0.24 0.24 0.21 0.34 0.35 0.28 0.21 0.24 0.33 0.23
Shareholders Equity per Share
0.19 0.38 0.36 0.42 0.55 0.63 0.76 0.73 1.43 1.34
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.19 0.38 0.36 0.42 0.55 0.63 0.76 0.73 1.43 1.34
Free Cash Flow
(19.44) (23.66) (29.24) 0.65 (23.90) (19.79) (32.30) (32.30) (31.64) (44.85)
Working Capital
47.79 37.02 20.48 41.02 64.43 36.23 51.03 29.55 35.74 16.80
Capital Expenditures
(0.52) (0.56) (0.67) (0.41) (0.34) (0.04) (0.36) (1.41) (1.13) (2.53)
Net Current Asset Value
(10.08) 14.79 (0.55) 8.27 27.90 31.18 43.29 26.94 33.65 13.59
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.04 0.06 0.08 0.03 0.08 0.02 0.10 0.28 0.33 0.43
Net Profit Margin
(436.47%) (195.90%) (240.20%) (178.69%) (990.99%) (1,130.83%) (333.12%) (922.01%) (577.67%) 566.81%
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
6.03 0.25 0.35 0.12 0.18 0.34 0.38 0.56 0.71 0.94
Cash ROIC
(21.67%) (20.29%) (31.57%) (3.55%) (19.05%) (18.57%) (28.25%) (29.83%) (17.79%) (30.94%)
Accounts Receivable Turnover
19.04 13.74 17.17 0.58 0.17 0.15 0.25 1.47 1.65 4.23
Accounts Payable Turnover
0.02 0.06 0.09 0.04 0.08 0.06 0.07 0.05 0.03 0.04
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
17,952.50 5,941.63 3,410.66 4,315.82 7,158.97 6,459.08 4,629.83 7,811.24 12,423.04 7,283.69
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
0.76 0.69 0.52 25.57 25.42 11.97 13.83 3.38 2.10 1.40
Average Payables
6.31 5.85 7.44 18.29 17.39 6.02 5.84 6.09 6.43 8.26
Average Assets
112.90 107.12 112.34 149.10 141.25 116.71 113.57 137.45 157.91 118.62
Average Common Equity
60.18 69.52 66.98 81.42 93.01 103.19 101.75 128.25 147.39 103.48

Fold the line items

Columns are period end dates